Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success

Cancer Treat Res Commun. 2018:17:1-7. doi: 10.1016/j.ctarc.2018.08.002. Epub 2018 Aug 17.

Authors

Morgan Pantuck¹, Nicolaos Palaskas², Alexandra Drakaki³

Affiliations

¹ Department of Urology, Weill Cornell Medicine, USA. Electronic address: [email protected].
² Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, USA. Electronic address: [email protected].
³ Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, USA. Electronic address: [email protected].

PMID: 30170288
DOI: 10.1016/j.ctarc.2018.08.002

No abstract available

Keywords: CAR; Immunotherapy; T-cell; TCR; bladder cancer; genitourinary; kidney cancer; prostate cancer.

Publication types

Review

MeSH terms

Bioengineering / methods
Electrochemotherapy
Genes, Switch / physiology
Genes, Transgenic, Suicide / physiology
Humans
Immunotherapy / methods*
Immunotherapy / trends
Immunotherapy, Adoptive / methods
Immunotherapy, Adoptive / trends
Receptors, Chimeric Antigen / therapeutic use
Receptors, Notch / physiology
Signal Transduction / physiology
T-Lymphocytes*
Tissue Scaffolds
Tumor Microenvironment / physiology
Urogenital Neoplasms / therapy*

Substances

Receptors, Chimeric Antigen
Receptors, Notch